Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 1/20 | 0.53 |
| ▸ | P2RY14 | Q15391 | 5/20 | 0.51 |
| ▸ | P2RY2 | P41231 | 10/20 | 0.46 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.46 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.45 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.44 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19026959 | 1.00 | TYMP (0.53) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL15302883 | 1.00 | TYMP (0.53) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL26647610 | 1.00 | TYMP (0.53) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL4582323 | 1.00 | TYMP (0.53) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL22983983 | 1.00 | TYMP (0.53) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL22983986 | 1.00 | TYMP (0.53) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL19026961 | 1.00 | TYMP (0.53) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL22983977 | 1.00 | TYMP (0.53) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL17556244 | 0.93 | TYMP (0.53) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL3316264 | 0.93 | P2RY14 (0.51) | TYMPP2RY14P2RY2P2RY6P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302995-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | SHIVALILA CHIKDU SHAKTI (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250262235-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD (SG) | 2025-08-21 | — | — | US | disclosed |
| US-20250135036-A1 | COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2025-05-01 | — | — | US | disclosed |
| EP-4522744-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2025-03-19 | — | — | EP | disclosed |
| EP-4507700-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | Wave Life Sciences Ltd. (SG) | 2025-02-19 | — | — | EP | disclosed |
| EP-4404942-A2 | COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2024-07-31 | — | — | EP | disclosed |
| WO-2023220440-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220428-A1 | COMPOSITIONS FOR EDITING ASS1 TRANSCRIPTS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023201095-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-10-19 | — | — | WO | disclosed |
| WO-2023049477-A2 | COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-03-30 | — | — | WO | disclosed |
| US-10730904-B2 | Method for liquid-phase synthesis of nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-04 | — | — | US | disclosed |
| EP-2921499-B1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACIDS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-01-22 | — | — | EP | disclosed |
| US-20190135852-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-09 | — | — | US | disclosed |
| EP-2921499-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | Takeda Pharmaceutical Company Limited (JP) | 2015-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302995-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | ADAR, NSUN2, RNGTT | TYMP 82/4885P2RY14 895/4885P2RY2 521/4885 |
| US-20250262235-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | ADAR, RNGTT, NSUN2 | TYMP 36/4885P2RY14 2992/4885P2RY2 2916/4885 |
| US-20190135852-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | RNGTT, POLR2H, POLR2E | TYMP 165/4885P2RY14 3644/4885P2RY2 3721/4885 |
| US-20250135036-A1 | COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF | MECP2, ADAR, NSUN2 | TYMP 1801/4885P2RY14 3375/4885P2RY2 3201/4885 |
| US-10730904-B2 | Method for liquid-phase synthesis of nucleic acid | RNGTT, POLR2H, POLR2E | TYMP 257/4885P2RY14 3902/4885P2RY2 3590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.